Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug [MarketWatch]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: MarketWatch
Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug Lexicon Pharmaceuticals Inc. shares LXRX, -0.84% slid 15% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has denied its appeal of a decision relating to a diabetes treatment. The Woodlands, Texas-based company said the FDA denied its appeal of a Complete Response Letter relating to its new drug application for sotagliflozin in type 1 diabetes. The company said it would appeal the decision and will hold a conference call at 8.00 a.m. Eastern. The FDA issued the Complete Response Letter, a ruling that means it cannot accept a NDA in its present form, back in February. Lexicon shares have fallen 47% in 2019, while the S&P 500 SPX, -0.40% has gained 25%.
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)GlobeNewswire
- Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)GlobeNewswire
LXRX
Earnings
- 11/12/24 - Miss
LXRX
Sec Filings
- 12/16/24 - Form 3
- 12/9/24 - Form SC
- 12/2/24 - Form 4
- LXRX's page on the SEC website